Literature DB >> 15389184

Rosacea: II. Therapy.

Michelle T Pelle1, Glen H Crawford, William D James.   

Abstract

Despite an incomplete understanding of the pathogenesis of rosacea, therapeutic modalities continue to expand. The principal subtypes of rosacea include erythematotelangiectatic rosacea, papulopustular rosacea, phymatous rosacea, and ocular rosacea. These phenotypic expressions are probably caused by divergent pathogenic factors and consequently respond to different therapeutic regimens. A subtype-directed approach to therapy is discussed in part II of this review. We provide an overview of the available topical, oral, laser, and light therapies in the context of these cutaneous subtypes, review the evidence that supports their use, and outline their therapeutic approach. Suggestions for future areas of study also are provided. Learning objective At the completion of this learning activity, participants should be familiar with the subtype-directed approach to therapy for rosacea including available topical, oral, laser, and light therapies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15389184     DOI: 10.1016/j.jaad.2004.03.033

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  36 in total

1.  Use of oral isotretinoin in the management of rosacea.

Authors:  Hyunhee Park; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2011-09

2.  Comprehensive medical management of rosacea: an interim study report and literature review.

Authors:  James Q Del Rosso; Eric W Baum
Journal:  J Clin Aesthet Dermatol       Date:  2008-05

3.  Trends in the frequency of original research in acne vulgaris, rosacea, dermatitis, psoriasis, skin cancer, and skin infections, 1970-2010.

Authors:  Young M Choi; Jashin J Wu
Journal:  Perm J       Date:  2015

4.  Tetracycline suppresses ATP gamma S-induced CXCL8 and CXCL1 production by the human dermal microvascular endothelial cell-1 (HMEC-1) cell line and primary human dermal microvascular endothelial cells.

Authors:  Anna Bender; Tamar Zapolanski; Shannon Watkins; Ava Khosraviani; Kristina Seiffert; Wanhong Ding; John A Wagner; Richard D Granstein
Journal:  Exp Dermatol       Date:  2008-03-13       Impact factor: 3.960

5.  Rosacea: a review.

Authors:  Brittney Culp; Noah Scheinfeld
Journal:  P T       Date:  2009-01

Review 6.  Kallikrein 5-mediated inflammation in rosacea: clinically relevant correlations with acute and chronic manifestations in rosacea and how individual treatments may provide therapeutic benefit.

Authors:  Aimee M Two; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2014-01

7.  Novel photopneumatic therapy for the treatment of rosacea.

Authors:  Jun Hyung Kim; Seung Ho Chang; Mi Kyung Cho; Bang Soon Kim
Journal:  Ann Dermatol       Date:  2009-08-31       Impact factor: 1.444

Review 8.  Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature.

Authors:  Michael O Griffin; Eduardo Fricovsky; Guillermo Ceballos; Francisco Villarreal
Journal:  Am J Physiol Cell Physiol       Date:  2010-06-30       Impact factor: 4.249

9.  Clinical evaluation of 168 korean patients with rosacea: the sun exposure correlates with the erythematotelangiectatic subtype.

Authors:  You In Bae; Sook-Jung Yun; Jee-Bum Lee; Seong-Jin Kim; Young Ho Won; Seung-Chul Lee
Journal:  Ann Dermatol       Date:  2009-08-31       Impact factor: 1.444

10.  In Schizophrenia, Deficits in Natural IgM Isotype Antibodies Including those Directed to Malondialdehyde and Azelaic Acid Strongly Predict Negative Symptoms, Neurocognitive Impairments, and the Deficit Syndrome.

Authors:  Michael Maes; Buranee Kanchanatawan; Sunee Sirivichayakul; André F Carvalho
Journal:  Mol Neurobiol       Date:  2018-11-27       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.